KRAS mutationLung cancerLung adenocarcinomaErlotinib resistanceTargeted therapyMEK inhibitionSelumetinibPI3K inhibitionmTOR inhibitionHsp90 inhibitionKRAS-mutant lung cancers account for approximately 25 % of non-small cell lung carcinomas, thus representing an enormous burden of cancer worldwide. KRAS mutations...
Kirsten rat sarcoma viral oncogene homologue (KRAS) is the best-known oncogene with the highest mutation rate among all cancers and is associated with a series of highly fatal cancers, including pancreatic ductal adenocarcinoma (PDAC), nonsmall-cell lung cancer (NSCLC), and colorectal cancer (CRC...
Mutation rates for KRAS were acquired from the Cancer Facts & Figs. 2000 report published by the American Cancer Society and published articles [26]. CRC, colorectal cancer; LUAD, lung adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; IDC, invasive ductal carcinoma; STAD, stomach ...
[1]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [2]. Cox A D, Der CJ. Ras history: The saga continues[J]. Small GTPases, 2010, 1(1): 2-27.[3]. Santos E,Martin-Zanca D, Reddy E...
Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. ...
An analysis of 43 KRAS mutant NSCLC patients who were enrolled in the BATTLE-1 (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial determined that KRAS mutation variants G12C and G12V were significantly associated with worse median PFS compared to other ...
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that ...
3.https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug 4.https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc...
[1] FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy. Retrieved May 28, 2021, from https://www.prnewswire.com/news-releases/fda-approves-first-targeted-therapy-fo...
et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol. Cancer Ther. 10, 336–346 (2011). CAS PubMed PubMed Central Google Scholar McCormick, F. Progress in targeting RAS with small molecule drugs. ...